Ladiratuzumab

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683) . Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) [1][2].

Product Specifications

CAS Number

[1629760-28-6]

Product Name Alternative

HLIV22

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ladiratuzumab.html

Purity

99.95

Solubility

10 mM in DMSO

Smiles

[Ladiratuzumab]

Molecular Weight

(146.96 kDa)

References & Citations

[1]Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142.|[2]Cao, et al. Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Research 78.13_Supplement (2018) : 2742-2742.